News for DURECT Corporation (DRRX)

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded down 0.40% to 44,658.06 while the NAS...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.4% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.02...

California-based DURECT Corporation (DRRX) is up over 267 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Durect Corporation (DRRX) stock soars 258% after Bausch Health (BHC) agrees to acquire the company for $63M upfront cash. Read more here.

PR NewswireCUPERTINO, Calif., May 13, 2025 Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline resu

DURECT Corporation (DRRX) reported Q1 2025 revenues of $0.3 million and a net loss of $4.2 million. Cash position dropped to $8.4 million from $12.0 million

Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ETCompany ParticipantsTim Papp - Chief Financial OfficerJim Brown -...

Durect (DRRX) delivered earnings and revenue surprises of -200% and 93.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

DURECT (DRRX) to release Q4 earnings on March 26 post-market. Analysts predict EPS of -$0.02 (+80% Y/Y) and $6.91M revenue (+158.8% Y/Y).

PR NewswireCUPERTINO, Calif., March 19, 2025 CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceu

Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PR NewswireCUPERTINO, Calif., Nov. 25, 2024 CUPERTINO, Calif., Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceuti

DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsJim Brown - Co-Founder, Chief Executive...

Durect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) experienced a notable stock surge with shares rising by 5.01%. The stock was last reported at $4.40 per share with a trading vol

Aug 13, 2024 / 08:30PM GMTOperator Ladies and gentlemen, welcome to the DURECT Corporation second-quarter 2024 earnings conference call. (Operator Instructions)